Roy van der Meel

Roy van der Meel

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Roy van der Meel

Eindhoven University of Technology

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
AAAkin Akinc
Akin Akinc
MMMartin A. Maier
Martin A. Maier
MMMuthiah Manoharan
Muthiah Manoharan
KFKevin Fitzgerald
Kevin Fitzgerald
MJMuthusamy Jayaraman
Muthusamy Jayaraman
PCPieter Cullis
Pieter Cullis

31 May 2021 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
JKJayesh A. Kulkarni
Jayesh A. Kulkarni
DWDominik Witzigmann
Dominik Witzigmann
STSarah B. Thomson
Sarah B. Thomson
SCSam Chen
Sam Chen
BLBlair R. Leavitt
Blair R. Leavitt
RMRoy van der Meel
Roy van der Meel
The increasing number of approved nucleic acid therapeutics demonstrates the potential to treat diseases by targeting their genetic blueprints in vivo. Conventional treatments generally induce therapeutic effects that are transient because they target proteins rather than underlying causes. In contrast, nucleic acid therapeutics can achieve long-lasting or even curative effects via gene inhibition, addition, replacement or editing. Their clinical translation, however, depends on delivery technologies that improve stability, facilitate internalization and increase target affinity. Here, we review four platform technologies that have enabled the clinical translation of nucleic acid therapeutics: antisense oligonucleotides, ligand-modified small interfering RNA conjugates, lipid nanoparticles and adeno-associated virus vectors. For each platform, we discuss the current state-of-the-art clinical approaches, explain the rationale behind its development, highlight technological aspects that facilitated clinical translation and provide an example of a clinically relevant genetic drug. In addition, we discuss how these technologies enable the development of cutting-edge genetic drugs, such as tissue-specific nucleic acid bioconjugates, messenger RNA and gene-editing therapeutics.

6 November 2019 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
RMRoy van der Meel
Roy van der Meel
ESEinar Sulheim
Einar Sulheim
YSYang Shi
Yang Shi
Fabian KiesslingFabian Kiessling
Fabian Kiessling
WMWillem J. M. Mulder
Willem J. M. Mulder
Twan LammersTwan Lammers
Twan Lammers

1 January 2020 in Theranostics
Verified
Journal Article
Open access
YSYang Shi
Yang Shi
RMRoy van der Meel
Roy van der Meel
XCXiaoyuan Chen
Xiaoyuan Chen
Twan LammersTwan Lammers
Twan Lammers
Following its discovery more than 30 years ago, the enhanced permeability and retention (EPR) effect has become the guiding principle for cancer nanomedicine development. Over the years, the tumor-targeted drug delivery field has made significant progress, as evidenced by the approval of several nanomedicinal anticancer drugs. Recently, however, the existence and the extent of the EPR effect - particularly in patients - have become the focus of intense debate. This is partially due to the disbalance between the huge number of preclinical cancer nanomedicine papers and relatively small number of cancer nanomedicine drug products reaching the market. To move the field forward, we have to improve our understanding of the EPR effect, of its cancer type-specific pathophysiology, of nanomedicine interactions with the heterogeneous tumor microenvironment, of nanomedicine behavior in the body, and of translational aspects that specifically complicate nanomedicinal drug development. In this virtual special issue, 24 research articles and reviews discussing different aspects of the EPR effect and cancer nanomedicine are collected, together providing a comprehensive and complete overview of the current state-of-the-art and future directions in tumor-targeted drug delivery.

3 April 2018 in ACS Nano
Verified
Journal Article
Closed access
JKJayesh A. Kulkarni
Jayesh A. Kulkarni
MDMaria M. Darjuan
Maria M. Darjuan
JMJoanne E. Mercer
Joanne E. Mercer
SCSam Chen
Sam Chen
RMRoy van der Meel
Roy van der Meel
PCPieter Cullis
Pieter Cullis

1 June 2018 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
JKJayesh A. Kulkarni
Jayesh A. Kulkarni
PCPieter R. Cullis
Pieter R. Cullis
RMRoy van der Meel
Roy van der Meel
Genetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any disease can be treated by silencing a pathological gene, expressing a beneficial protein, or by editing defective genes. However, therapies based on nucleic acid polymers require sophisticated delivery systems to deliver these macromolecules to the interior of target cells. In this study, we review progress in developing nonviral lipid nanoparticle (LNP) delivery systems that have attractive properties, including ease of manufacture, reduced immune responses, multidosing capabilities, larger payloads, and flexibility of design. LNP systems represent the most advanced delivery systems for genetic drugs as it is expected that an LNP-short interfering RNA (siRNA) formulation will receive clinical approval from the Food and Drug Administration (FDA) in 2018 for treatment of the hereditary condition transthyretin-mediated amyloidosis, a fatal condition for which there is currently no treatment. This achievement is largely due to the development of optimized ionizable cationic lipids, arguably the most important factor in the clinical success of LNP-siRNA. In addition, we highlight potential LNP applications, including targeting tissues beyond the liver and therapeutic approaches based on messenger RNA or Clustered Regularly Interspaced Short Palindromic Repeats/Cas.